INTRODUCTION: Cushing syndrome (CS) of any etiology (adrenal, pituitary or ectopic) impacts negatively on health-related quality of life (QoL), especially in active hypercortisolism but also after endocrine cure. Both generic questionnaires like the short-form 36 health survey -SF-36- and the derived SF-12, or the Hospital Anxiety and Depression Scale (HADS), and disease-specific measures like the CushingQoL and the Tuebingen CD-25 questionnaires have provided information on the impact of CS on patients perceived health. MATERIALS AND METHODS: Studies published since January 2013 until November 2014 on QoL in patients with CS were identified, reviewed and summarized. CONCLUSIONS: Treatment of CS improves patients perceived QoL, but it often takes many months and often never normalizes. In parallel to persistent QoL impairment in cured CS, brain and cerebellar volume are reduced. Depression, anxiety and cognitive dysfunction are common. Pediatric patients with CS also present worse QoL than normal children, as well as additional issues like delayed growth and pubertal development, next to abnormal body composition, psychological and cognitive maturation. Fluoxetine has been suggested as a neuroprotectant and antidepressant for patients with CS, although no prospective studies are yet available. The CushingQoL questionnaire has been mapped to well-validated instruments like SF-36 or EQ-5D, and therefore may be used in cost-utility and other health economy studies.
INTRODUCTION:Cushing syndrome (CS) of any etiology (adrenal, pituitary or ectopic) impacts negatively on health-related quality of life (QoL), especially in active hypercortisolism but also after endocrine cure. Both generic questionnaires like the short-form 36 health survey -SF-36- and the derived SF-12, or the Hospital Anxiety and Depression Scale (HADS), and disease-specific measures like the CushingQoL and the Tuebingen CD-25 questionnaires have provided information on the impact of CS on patients perceived health. MATERIALS AND METHODS: Studies published since January 2013 until November 2014 on QoL in patients with CS were identified, reviewed and summarized. CONCLUSIONS: Treatment of CS improves patients perceived QoL, but it often takes many months and often never normalizes. In parallel to persistent QoL impairment in cured CS, brain and cerebellar volume are reduced. Depression, anxiety and cognitive dysfunction are common. Pediatric patients with CS also present worse QoL than normal children, as well as additional issues like delayed growth and pubertal development, next to abnormal body composition, psychological and cognitive maturation. Fluoxetine has been suggested as a neuroprotectant and antidepressant for patients with CS, although no prospective studies are yet available. The CushingQoL questionnaire has been mapped to well-validated instruments like SF-36 or EQ-5D, and therefore may be used in cost-utility and other health economy studies.
Authors: Susan M Webb; John E Ware; Anna Forsythe; Min Yang; Xavier Badia; Lauren M Nelson; James E Signorovitch; Lori McLeod; Mario Maldonado; Wojciech Zgliczynski; Christophe de Block; Lesly Portocarrero-Ortiz; Monica Gadelha Journal: Eur J Endocrinol Date: 2014-04-23 Impact factor: 6.664
Authors: Cornelie D Andela; Steven J A van der Werff; J Nienke Pannekoek; Susan M van den Berg; Onno C Meijer; Mark A van Buchem; Serge A R B Rombouts; Roos C van der Mast; Johannes A Romijn; Jitske Tiemensma; Nienke R Biermasz; Nic J A van der Wee; Alberto M Pereira Journal: Eur J Endocrinol Date: 2013-10-21 Impact factor: 6.664
Authors: Andrea Oßwald; Eva Plomer; Christina Dimopoulou; Monika Milian; Rainer Blaser; Katrin Ritzel; Anne Mickisch; Ferengis Knerr; Milan Stanojevic; Klaus Hallfeldt; Jochen Schopohl; Klaus A Kuhn; Günter Stalla; Felix Beuschlein; Martin Reincke Journal: Eur J Endocrinol Date: 2014-08 Impact factor: 6.664
Authors: A S Šojat; B Dunjić-Kostić; L V Marina; M Ivović; N V Radonjić; A Kendereški; A Ćirković; M Tančić-Gajić; Z Arizanović; S Mihajlović; S Vujović Journal: J Endocrinol Invest Date: 2021-02-02 Impact factor: 4.256
Authors: M J G van Manen; V L Wester; E F C van Rossum; L M van den Toorn; K Y Dorst; Y B de Rijke; M S Wijsenbeek Journal: PLoS One Date: 2019-06-14 Impact factor: 3.240
Authors: Cyro G S Leães; Matheus V Fernandes; Luiza Alves; Bruna Araújo; Carolina G S L Rech; Nelson P Ferreira; Luis H T Rosa; Júlia F S Pereira-Lima; Miriam C Oliveira Journal: Indian J Endocrinol Metab Date: 2019 Jul-Aug
Authors: Merel van der Meulen; Amir H Zamanipoor Najafabadi; Daniel J Lobatto; Cornelie D Andela; Thea P M Vliet Vlieland; Alberto M Pereira; Wouter R van Furth; Nienke R Biermasz Journal: Endocrine Date: 2020-06-19 Impact factor: 3.633